TABLE 3a COMPARISION PREVIOUS SIMILAR STUDY DESIGNS WITH THE PRESENT STUDY WITH RESPECT TO OABSS TOTAL SCORE IMPROVEMENT
AUTHOR
STUDY GROUP (mean change from baseline) CONTROL GROUP(S) (mean change from base line)
P-VALUE
Ichihara et al(7) (2013) Mirabegron(50mg) -2.21 + Tamsulosin(0.2mg)
Tamsulosin(0.2mg) -0.87
P - 0.012
Kakizaki(8) (2017) Mirabegron(50mg) -2.78 + Tamsulosin(0.2mg) Tamsulosin (0.2mg) -2.13 + placebo
P - 0.001
Present study Baseline(mean ± S.D) End point(mean ± S.D) Mean difference 7.95±2.80 2.33±1.18 -5.62 6.75±2.08 4.53±1.88 -2.22
P < 0.001
OABSS – Overactive bladder symptom score, S.D – Standard deviation. OABSS – Overactive bladder symptom score, S.D – Standard deviation. OABSS – Overactive bladder symptom score, S.D – Standard deviation. OABSS – Overactive bladder symptom score, S.D – Standard deviation.
TABLE 3b
COMPARISION PREVIOUS SIMILAR STUDY DESIGNS WITH THE PRESENT STUDY WITH RESPECT TO IPSS-S SCORE IMPROVEMENT TABLE 3b
COMPARISION PREVIOUS SIMILAR STUDY DESIGNS WITH THE PRESENT STUDY WITH RESPECT TO IPSS-S SCORE IMPROVEMENT TABLE 3b
COMPARISION PREVIOUS SIMILAR STUDY DESIGNS WITH THE PRESENT STUDY WITH RESPECT TO IPSS-S SCORE IMPROVEMENT TABLE 3b
COMPARISION PREVIOUS SIMILAR STUDY DESIGNS WITH THE PRESENT STUDY WITH RESPECT TO IPSS-S SCORE IMPROVEMENT
AUTHOR
STUDY GROUP (mean change from baseline) CONTROL GROUP(S) (mean change from base line)
P-VALUE
Ichihara et al(7) (2013) Mirabegron(50mg) -2.03 + Tamsulosin(0.2mg)
Tamsulosin(0.2mg) -0.42
P - 0.006
Kakizaki(8) (2017) Mirabegron(50mg) -2.29 + Tamsulosin(0.2mg) Tamsulosin (0.2mg) -1.51 + placebo
P < 0.001
Present study Baseline(mean ± S.D) End point(mean ± S.D) Mean difference 12.68±2.71 3.27±1.26 -9.40 10.97±3.02 6.38±2.16 -7.48
P < 0.001
IPSS-S: IPSS storage subscore, S.D – Standard deviation. IPSS-S: IPSS storage subscore, S.D – Standard deviation. IPSS-S: IPSS storage subscore, S.D – Standard deviation. IPSS-S: IPSS storage subscore, S.D – Standard deviation.
TABLE 3c
COMPARISION OF SIMILAR STUDIES WITH THE PRESENT STUDY WITH RESPECT TO CHANGE IN PVR TABLE 3c
COMPARISION OF SIMILAR STUDIES WITH THE PRESENT STUDY WITH RESPECT TO CHANGE IN PVR TABLE 3c
COMPARISION OF SIMILAR STUDIES WITH THE PRESENT STUDY WITH RESPECT TO CHANGE IN PVR TABLE 3c
COMPARISION OF SIMILAR STUDIES WITH THE PRESENT STUDY WITH RESPECT TO CHANGE IN PVR
AUTHOR
STUDY GROUP (mean change from baseline) CONTROL GROUP(S) (mean change from the baseline)
P-VALUE
Ichihara et al(7) (2013) Mirabegron(50mg) 37.3 + Tamsulosin(0.2mg)
Tamsulosin(0.2mg) 3.9
P – 0.020
Kakizaki et al (8) (2017) Mirabegron(50mg) 2.72 + Tamsulosin(0.2mg) Tamsulosin (0.2mg) -0.97 + placebo
P - 0.059
Present study Baseline(mean ± S.D) End point(mean ± S.D) Mean difference 58.38±68.79 51.17±51.32 -7.20 79.35±119.39 49.08±70.07 -30.27
P – 0.136
PVR- Post void residual urine, S.D – Standard deviation. PVR- Post void residual urine, S.D – Standard deviation. PVR- Post void residual urine, S.D – Standard deviation. PVR- Post void residual urine, S.D – Standard deviation.